NuVasive Inc (NUVA)
41.30
+0.66
(+1.62%)
USD |
NASDAQ |
Mar 31, 16:00
41.32
+0.02
(+0.05%)
After-Hours: 20:00
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 2.156B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -27.16% |
| Valuation | |
| PE Ratio | 58.17 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 2.049 |
| Price to Book Value | 2.481 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 1.027 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 59.55% |
News
Headline
Wire
Time (ET)
Globe Newswire
03/30 09:43
Globe Newswire
03/29 16:35
PR Newswire
03/28 11:50
Globe Newswire
03/24 08:52
PR Newswire
03/23 15:04
Globe Newswire
03/22 15:50
Events
| DATE | TIME | TYPE | PERIOD | REPORTED EPS |
ESTIMATED EPS |
SURPRISE | |
| 05/04/2023* | -- | Results | Q1 2023 | -- | 0.42 | -- | |
| 05/04/2023* | 16:30 EST | Earnings Call | Q1 2023 | -- | -- | -- | |
| 02/22/2023 | -- | Results | Q4 2022 | 0.43 | 0.51 | -15.62% | |
| 02/22/2023 | 16:30 EST | Earnings Call | Q4 2022 | -- | -- | -- | |
| 11/09/2022 | -- | Results | Q3 2022 | 0.54 | 0.54 | 0.40% | |
| 11/09/2022 | 16:30 EST | Earnings Call | Q3 2022 | -- | -- | -- | |
| 08/03/2022 | -- | Results | Q2 2022 | 0.47 | 0.56 | -15.91% | |
| 08/03/2022 | 16:30 EST | Earnings Call | Q2 2022 | -- | -- | -- |
*Estimated Date/Time
Earnings
Profile
| NuVasive Inc is a medical technology company focused on developing, manufacturing, selling and providing procedural solutions for spine surgery, with a guiding purpose to transform surgery, advance care and change lives. The company has a portfolio of procedurally integrated spine surgery solutions, including surgical access instruments, spinal implants, fixation systems, biologics, and enabling technologies, as well as systems and services for intraoperative neuromonitoring. It also develop and sell magnetically adjustable implant systems for spine and specialized orthopedic procedures. |
| URL | https://www.nuvasive.com |
| Investor Relations URL | https://ir.nuvasive.com/ |
| HQ State/Province | Colorado |
| Sector | Healthcare |
| Industry | Medical Devices |
| Equity Style | Small Cap/Blend |
| Next Earnings Release | May. 04, 2023 (est.) |
| Last Earnings Release | Feb. 22, 2023 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Dividends
| Dividend Per Share (TTM) | -- |
|
2017
2018
2019
2020
2021
6.00%
4.00%
2.00%
|
|
| Yield to Market | 0.00 |
| Yield to Sector | 0.00 |
| Yield to Industry | 0.00 |
| Last Dividend Amt. | -- |
| Dividend Frequency | -- |
| Last Ex-Dividend Date | -- |
| Yield (TTM) | 0.00% |
| Forward Yield | -- |
| Payout Ratio | 0.00% |
| Cash Payout Ratio | 0.00% |
| Consistent Payer (5Y) | No |
| Consistent Growth (5Y) | No |
Risk
Total Returns Comparison
Annual Total Returns Versus Peers
As of March 31, 2023.
Fundamentals
| Revenue (TTM) | 1.202B |
| Total Expenses (TTM) | 1.119B |
| Net Income (TTM) | 40.41M |
| Total Assets (Quarterly) | 2.225B |
| Total Liabilities (Quarterly) | 1.356B |
| Shareholders Equity (Quarterly) | 868.89M |
| Cash from Operations (TTM) | 169.12M |
| Cash from Investing (TTM) | -155.19M |
| Cash from Financing (TTM) | -8.59M |
Ratings
Profile
| NuVasive Inc is a medical technology company focused on developing, manufacturing, selling and providing procedural solutions for spine surgery, with a guiding purpose to transform surgery, advance care and change lives. The company has a portfolio of procedurally integrated spine surgery solutions, including surgical access instruments, spinal implants, fixation systems, biologics, and enabling technologies, as well as systems and services for intraoperative neuromonitoring. It also develop and sell magnetically adjustable implant systems for spine and specialized orthopedic procedures. |
| URL | https://www.nuvasive.com |
| Investor Relations URL | https://ir.nuvasive.com/ |
| HQ State/Province | Colorado |
| Sector | Healthcare |
| Industry | Medical Devices |
| Equity Style | Small Cap/Blend |
| Next Earnings Release | May. 04, 2023 (est.) |
| Last Earnings Release | Feb. 22, 2023 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ownership
| Insider Ownership Percentage | Upgrade |
Jul '20
Nov '20
Mar '21
80.00%
40.00%
10.00%
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Other Resources
| Whale Wisdom | 13F Filings |
| Seeking Alpha | Call Transcripts |
| Nasdaq | Insider Trading |
| Nasdaq | Institutional Ownership |
| Nasdaq | Option Chain |
| SEC | SEC Filings |
| NUVA Tweets |